N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIGB), may carry
radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such
as irinotecan and vincristine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving iodine I 131 MIGB
together with irinotecan and vincristine may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 MIGB
when given together with irinotecan and vincristine in treating young patients with resistant
or relapsed high-risk neuroblastoma.